MedTrace Logo

CRC Screening Using mSEPT9 (Methylated Septin 9) in Chinese Population

NCT02540850 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1031

Last updated 2016-01-11

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the performance of the SEPT9 gene methylation assay in Colorectal cancer (CRC) high-risk population in Chinese hospitals using the opportunistic screening method. The trial plans to evaluate a Chinese domestic SEPT9 assay kit produced by BioChain (Beijing) Science and Technology Corporation, who is a close partner of Epigenomics AG, the producer for Epi proColon 2.0 CE.

Conditions

Sponsors & Collaborators

  • Peking Union Medical College Hospital

    collaborator OTHER

  • General Hospital of Beijing PLA Military Region

    collaborator OTHER

  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    collaborator OTHER

  • Peking University Cancer Hospital & Institute

    collaborator OTHER

  • BioChain (Beijing) Science and Technology, Inc.

    lead INDUSTRY

Principal Investigators

  • XIAOLIANG HAN, Ph.D. · BioChain (Beijing) Science and Technology, Inc.

Eligibility

Min Age
17 Years
Max Age
88 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2015-09-30
Completion
2015-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02540850 on ClinicalTrials.gov